Schroder Investment Management Group
BBOT

Schroder Investment Management Group’s BridgeBio Oncology BBOT Stock Holding History

Schroder Investment Management Group’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.87M Sell
244,441
-4,720
-2% -$39.4K ﹤0.01% 942
2026
Q1 		$2.16M Buy
+249,161
New +$2.68M ﹤0.01% 916

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Schroder Investment Management Group's BBOT Position: Q2 2026 in Review

Schroder Investment Management Group reduced its BridgeBio Oncology (BBOT) stake by 1.9% in Q2 2026, selling an estimated $39.4K and leaving 244,441 shares worth $1.87M. The position accounts for ﹤0.01% of the portfolio, ranked #942.

Schroder Investment Management Group first reported a position in BBOT in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.16M in Q1 2026. 65 funds tracked by Wall St. Rank hold BBOT as of Q2 2026.

  • Schroder Investment Management Group held 244,441 shares of BridgeBio Oncology worth $1.87M as of Q2 2026.
  • Schroder Investment Management Group sold 4,720 BridgeBio Oncology shares in Q2 2026, an estimated $39.4K.
  • BridgeBio Oncology made up ﹤0.01% of Schroder Investment Management Group's portfolio in Q2 2026, its #942 holding.
  • Schroder Investment Management Group first reported a position in BridgeBio Oncology in Q1 2026 and has held it in 2 quarters since.
  • Schroder Investment Management Group's BridgeBio Oncology position peaked at $2.16M in Q1 2026.
  • 65 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2026.

Based on Schroder Investment Management Group's 13F filing for Q2 2026, filed 13 Aug 2026.